Generare, a biotechnology company, has raised €20 million in a Series A funding round to scale its molecular discovery platform and expand its compound library derived from microbial genomes.
The round was co-led by Alven and Daphni, with participation from existing investors including Galion.exe, Teampact Ventures, and VIVES Partners. The funding will support team growth and the development of a proprietary dataset aimed at improving drug discovery processes.
What The Company Does
Founded in 2023 by Dr. Vincent Libis and Guillaume Vandenesch, Generare develops a platform that decodes microbial genomes to identify previously hidden chemical compounds. By analysing genetic data, the company uncovers new molecules with potential therapeutic applications.
Its approach focuses on building a structured library of compounds with defined chemical properties, biological activity, and relevance for drug development. These molecules are derived from natural evolutionary processes, offering alternatives to synthetic compound libraries traditionally used in pharmaceutical research.
The platform generates new molecular data that can be used by researchers to identify drug candidates and explore novel mechanisms of action.
Advertisement
Market Context / Industry Background
Drug discovery increasingly relies on large datasets to train computational models and identify promising compounds. However, much of the existing data is based on a limited set of known chemical structures, creating constraints on innovation.
Natural products have historically been a major source of pharmaceutical breakthroughs, but large portions of microbial chemistry remain unexplored. Advances in genomics and data analysis are enabling companies to access this previously inaccessible chemical diversity.
There is growing interest in expanding the range of available molecular data to improve discovery pipelines, particularly as the industry seeks new approaches to address complex diseases.
In this context, integrating artificial intelligence with high-throughput sequencing technologies is becoming a central strategy for pharmaceutical and biotechnology companies. By combining machine learning algorithms with genomic data, researchers can predict the biosynthetic potential of microorganisms and identify novel compounds more efficiently than through traditional laboratory methods. This shift not only accelerates the early stages of drug discovery but also reduces costs and failure rates associated with conventional screening processes.
Furthermore, the ability to explore untapped microbial ecosystems, including extreme or previously inaccessible environments, opens new frontiers for identifying bioactive molecules. As competition in the biotech sector intensifies, companies that can effectively leverage these data-driven approaches are likely to gain a significant advantage in developing next-generation therapeutics.
Founder / Investor Commentary
Guillaume Vandenesch, CEO and co-founder of Generare, highlighted the limitations of current drug discovery models, noting that the field often relies on recycled datasets. He emphasised that the company is focused on generating genuinely novel molecular data derived from evolutionary processes.
Dr. Vincent Libis, CSO and co-founder, pointed to the untapped potential of natural compounds, stating that the platform aims to build a large-scale library of evolution-derived molecules to support future pharmaceutical innovation.
Growth Plans / Use Of Funds
The €20 million investment will be used to scale Generare’s platform and expand its molecular library, with a target of exceeding 2,000 compounds by 2027 and more than 10,000 over the longer term.
The company also plans to nearly double its team, currently consisting of around 25 specialists in biology, chemistry, and engineering, to support continued research and development.
Generare is already working with research laboratories that are using its identified molecules to explore treatments for complex and life-threatening diseases.
About Generare
Generare is a biotechnology company focused on decoding microbial genomes to discover new chemical compounds for drug development. Founded in 2023. Headquartered in Paris. The company builds proprietary datasets of novel molecules derived from natural biological systems, aiming to improve the efficiency and outcomes of drug discovery.
